Thirty years of critical care medicine by Vincent, Jean-Louis et al.
Every day you may make progress. Every step may 
be fruitful. Yet there will stretch out before you an 
ever-lengthening, ever-ascending, ever-improving 
path. You know you will never get to the end of the 
journey. But this, so far from discouraging, only 
adds to the joy and glory of the climb.
Winston Churchill
Introduction
Critical care medicine is a relatively young discipline that 
has rapidly grown into a full-ﬂ  edged specialty. Demand 
for intensive care has steadily escalated, and the ratio of 
intensive care unit (ICU) to hospital beds is increasing 
everywhere. ICUs now hold a key position in all hospitals, 
and critical care physicians are responsible for managing 
the ever-increasing numbers of patients with complex, 
life-threatening medical and surgical disease. Perhaps 
nowhere else in clinical medicine has the evolution of 
technology and scientiﬁ  c advance been so apparent and 
new ideas, concepts, and discoveries moved so fast from 
bench to bedside. On the occasion of the 30th Inter-
national Symposium on Intensive Care and Emergency 
Medicine, we thought it would be instructive to put 
together some thoughts from a few of the leaders in 
critical care who have been actively involved in this ﬁ  eld 
over the years. However, as with many anniversaries, we 
look back over the last 30 years with mixed feelings. 
Despite considerable technological and scientiﬁ  c advances, 
we cannot help but feel a little disappointed that our 
discipline has made few ground-shaking steps forward, 
especially in therapeutics. Nevertheless, we should be 
pleased with the progress and improvements that have 
been made, notably in the process of care.
We have not made much progress in therapeutics …
To be honest, there have been very few major 
developments in critical care in terms of speciﬁ  c new 
treatments and cures over the last 30 years. Our success 
in translating the many advances in basic scientiﬁ  c know-
ledge and understanding of the pathobiology of 
syndromes, such as sepsis and acute respiratory distress 
syndrome (ARDS), to pharmacologic or biologic thera-
pies in order to interrupt injurious processes has been 
minimal, and this is due in part to the complex and 
variable nature of these disease processes, the hetero-
geneous nature of the patients who are aﬀ  ected, and the 
inadequate preclinical models currently available [1]. No 
‘magic bullets’ that have directly saved lives in hetero-
geneous groups of patients have been developed. Many 
prospective multicenter randomized trials have been 
conducted; in itself, this may be viewed as progress and 
evidence of increasing maturity. However, the vast 
majority of these trials have failed to demonstrate 
improved outcomes with the intervention under investi-
gation [2]. Even the encouraging ﬁ  ndings of single-center 
studies have not been reproduced in later multicenter 
trials: a good example of this is the concept of tight blood 
sugar control, in which the results from the initial single-
center study [3] could not be reproduced by the 
multicenter VISEP (Volume Substitution and Insulin 
Th  erapy in Severe Sepsis) [4], Glucontrol [5], or NICE-
SUGAR (Normoglycemia in Intensive Care Evaluation 
and Survival Using Glucose Algorithm Regulation) [6] 
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© 2010 BioMed Central Ltdstudies. Th   ere are many reasons for the apparent failure of 
randomized controlled trials to demonstrate improved 
outcomes with the interventions that have been tested: for 
example, the interventions were simply not eﬀ  ective, the 
studies were underpowered, and the selected mortality 
endpoint is inadequate or inappropriate. However, the 
main reason is likely related to the logistics of multicenter 
trials, which require the inclusion of a broad spectrum of 
patients and loose co-intervention controls.
If we consider just a few of the main areas of critical 
care medicine, the (limited) progress made in the last 
30 years seems disappointingly obvious:
•  Sepsis: Perhaps our main advance in the ﬁ  eld of sepsis 
has been the unraveling and greater understanding of 
the pathogenetic response, which oﬀ  ered hope for the 
development of eﬀ  ective therapies for sepsis. Unfor  tu-
nately, only activated protein C (aPC) has actually been 
licensed for use in such patients, and the eﬃ   cacy of 
this drug has been challenged. Numerous other 
antisepsis therapies have been tested, many in large 
multicenter phase III studies, yet have failed to show 
overall eﬀ  ectiveness in improving patient outcomes.
  Much has been said about the importance of early 
diagnosis of sepsis and the potential role of biomarkers, 
but we remain frustrated in our attempts to identify 
biomarkers that are speciﬁ  c for sepsis and that can be 
used for diagnosis, therapeutic guidance, or prognos-
tication. Th  e role of immunomodulatory nutritional 
solutions has also not been clariﬁ  ed.  Whether 
specialized nutrients, such as glutamine or omega-3 
fatty acids, are beneﬁ   cial remains uncertain. Apart 
from the eﬀ   ects of selenium on the reduction of 
secondary bacterial infection, no consistent eﬀ  ect has 
been shown for other drugs, such as glutamine (Peter 
Andrews, SIGNET [Scottish Intensive Care Glutamine 
or Selenium Evaluative Trial], personal communication).
•  Respiratory failure and ARDS: Progress has been made 
in the use of noninvasive mechanical ventilation, 
which is now widely employed and for which indica-
tions have been more clearly deﬁ   ned. Arguably, we 
have made major progress in the ventilatory treatment 
of patients with ARDS over the past 30 years through 
the recognition and avoidance of iatrogenic ventilator-
induced lung injury (VILI) by limiting tidal volumes 
and airway pressures [7]. However, we still have much 
to learn about the optimal ventilatory management of 
patients with ARDS. Less aggressive ventilation has 
clearly resulted in a reduced incidence of barotrauma, 
yet debate persists over the best lung protective 
ventilation strategy and how to optimally apply 
positive end-expiratory pressure (PEEP). We now have 
some evidence, albeit not strong, that ﬂ  uid balance is 
an important determinant of outcome in patients with 
acute lung injury (ALI), although our ability to 
accurately deﬁ   ne a level of preload to which ﬂ  uid 
therapy should be titrated remains elusive. Turning 
patients to the prone position also appears to be 
associated with reduced mortality rates in the most 
severe cases. Disappointingly, no speciﬁ  c pharma  co-
logic intervention showing clear outcome beneﬁ  t has 
been forthcoming, with approaches ranging from 
inhaled surfactant or nitric oxide to systemic 
administration of antioxidants or anti-inﬂ  ammatory 
agents. Although most studies do not show a clear 
beneﬁ  t of steroids in ARDS, their precise role remains 
controversial in these patients. Even though mortality 
rates may be decreasing [8], we are still left with many 
unanswered questions.
•  Cardiovascular diseases: Th  ere has been considerable 
progress in the management of acute myocardial 
infarction with early thrombolysis and percutaneous 
coronary intervention, although these are often applied 
outside the ICU. Although minor modiﬁ  cations  are 
endorsed on an almost yearly basis, cardiopulmonary 
resuscitation has not been shown to increase the 
number of lives saved, especially in patients already in 
the hospital. Th  e development of ultrasound for 
cardio  vascular diagnosis and monitoring has been a 
major advance, but we have made less progress 
regarding hemodynamic support of the failing 
circulation. We still rely on the same catecholamines, 
such as epi  nephrine, norepinephrine, and dobutamine. 
Th   e use of dopamine for renal support and as a ﬁ  rst-
line vasopressor agent has waned, but it has not been 
convincingly replaced by other drugs. Th   e problem of 
‘vasoparesis’ (resistance vessels unresponsive to 
catecholamines) is unresolved. We have rediscovered 
vasopressin, but there is much debate about its 
potentially beneﬁ  cial  eﬀ  ects.  Th  e introduction of 
phosphodiesterase inhibitors or levosimendan has not 
yielded major outcome beneﬁ  ts. We still await reliable 
agents that selectively improve ventricular function 
without risking ischemia, tachycardia, or unwanted 
vasoactive and other eﬀ  ects. Selective and titratable 
agents to control heart rate which do not adversely 
aﬀ  ect ventricular performance are also lacking, and 
how to improve right ventricular dysfunction and 
address pulmonary hypertension remain major 
unsolved problems.
•  Renal system: We now have a far greater understanding 
than before of the causes of acute kidney injury (AKI); 
however, this has not resulted in the development of 
eﬀ  ective renal protective strategies. Hemodialysis or 
hemoﬁ  ltration or both in various modalities are now 
routinely oﬀ   ered to critically ill patients with acute 
renal failure, yet randomized multicenter trials have 
not clearly established that one form of renal support 
or level of intensity over another impacts on patient 
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ous veno-venous hemoﬁ   ltration (CVVH) with or 
without associated dialysis could be seen as an advance 
because it greatly facilitates ﬂ  uid management and the 
provision of adequate nutrition, it has not been shown 
to be clearly superior to intermittent dialysis in terms 
of outcome.
•  Coagulation/anticoagulation: While low-molecular-
weight heparins oﬀ  er some functional advantages over 
unfractionated heparin and recently introduced 
alternatives, such as argatroban and leparudin, help 
obviate the risk of heparin-induced consequences, 
none has usurped the primacy of the heparins in 
delivering therapeutic anticoagulation within the ICU. 
Catheter-based interventions, such as locally infused 
thrombolytics and mechanical ablation, now help 
when anticoagulants alone are insuﬃ   cient  or 
contraindicated in the treatment of life-threatening 
thromboembolism. Th  e development of recombinant 
factor VIIa was initially hailed as a breakthrough to 
help limit bleeding; however, studies have shown only 
a reduction in the use of transfusions and that beneﬁ  t 
may be negated by an increased risk of thrombo-
embolic events. Hence, the European Medicines 
Agency (EMEA) has issued a speciﬁ  c warning that the 
drug should not be used outside its approved 
indications.
•  Neurological system: Advances have been made in 
terms of neuro-monitoring modalities and in treat-
ments for speciﬁ  c neurological disease (for example, 
thrombolytic therapy for ischemic stroke and thera-
peutic cooling after cardiac arrest). However, there 
have been relatively few advances in the approach to 
many other neurological processes requiring intensive 
care (for example, traumatic brain injury), and 
mortality and morbidity rates in such patients remain 
high. Th   e development of new drugs for neurological 
disorders has been particularly disappointing.
Too many syndromes?
By describing new entities and coining new syndromes, 
we thought that diagnosis would be more speciﬁ  c and 
studies could be performed more easily on more homo-
ge  neous groups of patients, thus aiding and abetting the 
development of new therapies. However, this may not be 
the case. For example, introducing the concept of the 
systemic inﬂ   ammatory response syndrome (SIRS) did 
not prove to be helpful, and whether the AKI approach is 
really better than acute renal dysfunction or failure is not 
at all certain. It could even be argued that existing 
deﬁ  nitions of ALI and ARDS have not resulted in better 
management given that the only positive study outcome 
is that we should limit tidal volumes and plateau airway 
pressure in patients meeting these criteria. We have 
ended up grouping many heterogeneous patients 
together; this may have contributed to our lack of 
therapeutic progress in this area.
Is less better?
Undoubtedly, we have learned over the past 30 years that 
more is not necessarily better. We have, in fact, realized 
that fewer interventions or less of a particular inter-
vention is frequently associated with better outcomes. 
Previously, a primary goal of acute care management was 
to restore all measured variables to their ‘normal’ values 
whether they were laboratory values, such as electrolytes, 
blood gases, or hematocrit, or physiological values, such 
as cardiac output or urine output. For example, we now 
use fewer blood transfusions since the multicenter 
Canadian study by Hebert and colleagues [10] that noted 
that a hemoglobin transfusion trigger of 7 g/dL resulted 
in no increase in mortality when compared with trans-
fusions to a hemoglobin of greater than 9 g/dL. Invasive 
hemodynamic monitoring (for example, the pulmonary 
artery catheter) has been largely replaced by technologies 
that are less invasive, even though these lack direct 
measures of pulmonary vascular pressures and mixed 
venous oxygen saturation.
Th   anks to the development of interventional radiology, 
numerous therapeutic interventions that once required 
surgery are now accomplished less invasively. Abscess 
drainage, stent placement, interruption of torrential 
gastro  intestinal bleeding, coiling of intracerebral 
aneurysms, and percutaneous coronary intervention are 
only a few salient examples. Mechanical ablation or 
localized infusion of thrombolytics can safely accomplish 
clot lysis in the setting of massive pulmonary embolism, 
often taking the place of surgical embolectomy or 
systemic thrombolysis. Loculated pleural eﬀ  usions and 
empyemas that once required thoracotomy for drainage 
can often be addressed by localized instillation of a 
ﬁ   brinolytic through a well-placed drainage catheter. 
When such problems cannot be addressed in this way, 
video-assisted thoracoscopic (rather than open thorax) 
procedures are quite often successful.
Lower tidal volumes are widely used in mechanically 
ventilated patients [7], and invasive mechanical ventila-
tion is increasingly replaced by noninvasive ventila  tory 
techniques, especially in acute-on-chronic respiratory 
failure and for immunosuppressed patients; nonetheless, 
its role in the treatment of patients with acute respiratory 
failure outside experimental settings continues to be 
controversial. Sedation is used less routinely and in lower 
doses; we now recognize that, whereas in the past most 
patients on mechanical ventilation were heavily sedated, 
using less sedation can facilitate weaning, prevent 
delirium and post-traumatic stress disorder, and reduce 
lengths of ICU stay and associated costs [11]. Th   e story of 
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Many studies evaluated complex variables and optimal 
methods of orchestrating the transition to spontaneous 
breathing. However, facilitated weaning has become the 
preferred, minimalist approach; when simple criteria are 
met (reversal or improvement in the reason for initiation 
of ventilation, absence of severe hypoxemia, relative hemo  -
dynamic stability, and an adequate level of conscious-
ness), the ventilator is simply stopped and the patient is 
placed on a T-piece or minimal pressure support for 
30 minutes and then reassessed; things could not be more 
elementary.
We have learned (perhaps the hard way, through our 
mistakes) how inappropriate or excessive use of potent 
antibiotics may lead to increased prevalence of 
antimicrobial resistance. Many ICUs are now faced with 
multiple organisms that are resistant to many of our 
common antibiotics. We have also learned that speciﬁ  c 
infections, such as ventilator-associated pneumonia 
(VAP), can be cured by a shorter course of antibiotics.
Feeding has also become simpler, with fewer calories 
and fewer specialized nutrients. Fewer chest radiographs 
are performed, arterial blood gas measurements are less 
frequently requested, and the ventilator circuitry is 
changed less frequently. We now tolerate greater degrees 
of physiological abnormality in the critically ill (for 
example, in carbon dioxide, hemoglobin, and blood 
pressure) rather than drive the patient harder to achieve 
‘normal’ values. Clearly, multiple aspects of intensive care 
management have become less invasive and less intensive 
(Box 1).
… but we have made considerable progress in 
other aspects of patient management
Although no huge leaps have been made in new therapies 
for intensive care patients, marked advances have been 
made in the process of care. Th  ese advances, when 
implemented, can impact less directly, but no less 
importantly, on patient outcomes.
• Critical care medicine has established itself as a 
specialty in its own right, and the importance of 
intensivist-led care in optimizing outcomes has been 
demonstrated. Th  e approach to patient care has 
gradually evolved from a rather paternalistic, 
physician-directed process to a comprehensive, 
multidisciplinary, multi  pro  fessional team approach. 
Regular bedside rounds and 24-hour intensivist-led 
care have been associated with better outcomes. 
Unquestionably, the formation of multidisciplinary 
teams has improved care delivery. Nurses, physio-
therapists, pharmacists, and other team members are 
increasingly responsible for executing management 
protocols, including weaning, sedation, nutrition, 
glucose control, vasopressor and electrolyte manipu-
lation, patient positioning, and early ambu  lation. 
Checklists such as the FASTHUG (Feeding, Analgesia, 
Sedation, Th  romboembolic prophylaxis, Head-of-bed 
elevation, stress Ulcer prevention, and Glucose 
control) [12] have been introduced to encourage this 
team approach and to provide a simple mnemonic-
based reminder of the important ‘routine’ aspects of 
patient care. Goal-directed orders are increasingly 
common. Proto  colized care has been advocated, 
although not all agree that it is beneﬁ   cial and it 
remains a subject of intense debate. Th   e same is true 
for the use of guidelines to standardize care [13].
• We recognize that ‘time is tissue’ and that early 
eﬀ  ective management is crucial to maximize patient 
outcomes in all disease processes, including trauma 
management, percutaneous coronary intervention for 
myocardial infarc  tion, early administration of adequate 
ﬂ   uids and appropriate antibiotics in sepsis, early 
thrombolysis in stroke, and perioperative hemo-
dynamic optimization.
• We now manage ﬂ   uid balance more eﬀ  ectively, 
adminis  tering more ﬂ  uids in the acute resuscitation 
phase and then more actively removing excess ﬂ  uids 
later on, when the patient has stabilized. Th  e  develop-
ment of CVVH has helped in this regard. A conser-
vative ﬂ   uid strategy adopted once the patient is no 
longer in shock results in faster weaning from 
mechanical ventilation in ARDS patients [14].
• Th  e approach to patient care is more humane and 
personal. Th  e ICU is much more open to visits by 
family members. Communication with patients and 
relatives has certainly improved. Ethical issues, 
Box 1. Progress that has been made in critical care 
medicine over the past 30 years
By removing or limiting interventions:
-  Gentle ventilation and avoidance of large tidal volumes in 
acute respiratory distress syndrome
-  Increased use of noninvasive mechanical ventilation
- Less  sedation
-  Caloric intake that is less generous and avoidance of total 
parenteral nutrition
-  Monitoring systems that are less invasive
-  Less use of inotropic agents to increase oxygen delivery to 
predetermined levels
-  Less use of antiarrhythmic agents
-  Fewer blood transfusions
-  Restrictive antibiotic therapies
By increasing or adding interventions:
-  Activated protein C in severe sepsis (?)
-  Active mobilization (?)
-  Selective digestive decontamination (?)
Vincent et al. Critical Care 2010, 14:311 
http://ccforum.com/content/14/3/311
Page 4 of 8including decisions on end-of-life care, are also more 
openly discussed.
•  We mobilize our patients better and sooner, leading to 
reduced risks of VAP, thrombophlebitis, decubitus 
ulcers, and delirium.
•  We have identiﬁ  ed critical care as one important piece 
in a complex continuum of care and recognize its 
holistic nature. Few other specialties deal with the 
whole body, including the mind. Th   e physiological and 
psychological aspects of critical illness, the recovery 
processes (both short- and long-term), and the impact 
upon not only the patient but their loved ones are 
increasingly appreciated and managed.
•  We pay more attention to avoiding potential errors, to 
encouraging error reporting, and to managing errors 
better when they occur, having learned from the airline 
industry how to deal with these complex and 
occasionally fraught situations (crew resource manage-
ment). Increased use of electronic medical records and 
prescriptions may also help reduce errors.
• We have begun to evaluate the limited evidence 
available to support some established therapies and 
question their place in modern intensive care. Studies 
have been conducted to evaluate issues of ongoing 
uncertainty, such as the safety of albumin [15], the 
pulmonary artery catheter [16], and dopamine as a 
ﬁ   rst-line agent in shock [17], providing important 
infor  mation on some of the many aspects of clinical 
practice which are widely used but unproven.
•  We are more aware of the risks of nosocomial infection 
and the importance of preventive measures (starting 
with good hygiene, including hand washing), which we 
are applying more routinely and more eﬀ  ectively.
•  We understand better the determinants of mortality in 
the patient with critical illness, in particular the roles 
of prior diseases and of the presence, degree, pattern, 
and evolution of multiple organ dysfunction/failure. 
We have achieved a better understanding of underlying 
disease processes, including the complex patho  physio-
logy of sepsis, the heterogeneous nature of ARDS, the 
important role of the intra-abdominal compartment 
syndrome, and more subtle matters such as increased 
awareness of relative adrenal or vasopressin insuf-
ﬁ  ciency or both in patients in circulatory shock.
• We have learned much about the epidemiology of 
critical illness. We have complemented single-center, 
physiologically focused, and mechanism-probing in-
ves  ti  gations with national and international collabora-
tive studies centered on eﬀ   ectiveness. Large multi-
center and multinational registries have appeared and 
evolved for purposes of benchmarking and quality 
assurance (for example, ICNARC [Intensive Care 
National Audit and Research Centre], GiViTi [Gruppo 
Italiano per la Valutazione degli interventi in Terapia 
Intensiva], and ASDI [Austrian Center for Documen-
tation and Quality Assurance in Intensive Care 
Medicine]) or for purposes of research (for example, 
ANZICS [Australian and New Zealand Intensive Care 
Society] or ESICM [European Society of Intensive 
Care Medicine] ﬂ  u registries). Several large national 
and international consortiums (for example, ARDSNet, 
Canadian Critical Care Trials Group [CCCTG], 
ANZICS, Sepsis Occurence in Acutely ill Patients 
[SOAP], and European Critical Care Research Network 
[ECCRN]) have been created to facilitate the perfor-
mance of large multicenter clinical trials and 
observational studies to address important questions.
•  International collaboration between experts and 
scientiﬁ  c societies in programs such as the Surviving 
Sepsis Campaign has highlighted the importance of 
critical illness and led to the development of evidence-
based guidelines for sepsis [18] and, importantly, 
mechanisms to assess the eﬀ   ectiveness of their 
implementation.
The pendulum of medicine
As we look back over the past 30 years, we frequently see 
evidence of the so-called pendulum eﬀ  ect. Clinical trials 
of several interventions have yielded apparently conﬂ  ict-
ing, even opposing, results as the pendulum has swung 
from a beneﬁ  t eﬀ  ect through no eﬀ  ect to potential harm 
and then all the way back to beneﬁ  t, leaving the practicing 
clinician rather confused. We can oﬀ  er several examples:
•  Forty years ago, high-dose steroids were administered in 
sepsis for their anti-inﬂ  ammatory properties [19]. Studies 
then suggested that, in fact, steroids were ineﬀ  ective or 
even potentially harmful and so their use in sepsis 
decreased. Subsequent trials then suggested that smaller 
doses could help reduce vasopressor require  ments in 
patients with septic shock and possibly reduce mortality. 
However, a large inter  national multi  center study failed to 
conﬁ  rm these results [20], and steroid use in sepsis has 
again decreased. We are currently left with a recom-
mendation to consider the use of steroids in only the 
most severe forms of septic shock despite strong 
discussion about the risk/beneﬁ  t cutoﬀ   [18].
•  Tight blood g      lucose control was widely adopted after 
the single-center study results of Van den Berghe and 
colleagues [3], but multicenter studies later suggested 
that perhaps it was not such an easy approach to apply 
[4-6] and highlighted the diﬃ   culty  of  translating 
single-study results to the wider ICU population. But 
will the pendulum swing back again as automated 
monitoring systems are developed for continuous and 
accurate monitoring that will help to reduce the hypo-
glycemic episodes and as a greater emphasis is placed 
on avoiding glucose variability rather than on 
restricting blood glucose to normal levels?
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(Protein C Worldwide Evaluation in Severe Sepsis) 
results showing improved outcomes [21]; however, 
subsequent trial data and concerns about bleeding 
have dampened initial enthu  siasm. Th  ese  ﬁ  ndings led 
some investigators to challenge the results, and the 
EMEA requested a second placebo-controlled phase 
III study [21]. What will the results of the ‘repeat’ 
randomized control trial (PROWESS-SHOCK) do to 
the aPC pendulum?
• Initial excitement regarding the relatively simple 
approach of aggressive resuscitation using central 
venous oxygen saturation (ScvO2) as a target in a single 
center [22] has given way to questions about the need 
for blood transfusions in the resuscitation of patients 
with sepsis and the overall eﬃ     cacy of early goal-
directed therapy. At present, three large multicenter 
trials are addressing this question. Will their results 
also swing the pendulum?
• Th   e use of PEEP has swung from relatively high levels 
to relatively low levels and back to somewhat higher 
levels. Will the evidence for low tidal volumes and 
higher PEEP converge to make high-frequency ventila-
tion an optimal approach to limit VILI?
The next 30 years?
Given the complex nature of intensive care patients and 
the disease processes underlying their admission, it 
seems unlikely that the next 30 years will see the 
discovery of single therapeutic interventions that, acting 
alone, will have a major impact on all patients of a given 
broadly deﬁ  ned class. Th   is is perhaps most apparent for 
the treatment of patients with sepsis. Mono-therapies for 
sepsis may be doomed to failure given the multiple 
redundant and reciprocating autonomic and cellular 
processes, intracellular pathways, diﬀ  erent expression of 
common injury, variable times of presentation and 
diﬀ   ering initial clinical status, and variable levels of 
organ-system reserve, genetic predisposition, and nutri-
tional state. Rather, we will continue to make incremental 
stepwise advances as our understanding of critical illness 
continues to expand. Various factors will help in this 
process. We envision the following:
•  Improved communication between basic scientists and 
ICU physicians will enhance translational research and 
lead to the development of preclinical models that are 
more clinically relevant.
• Th   e use of nonlinear complexity models of health and 
disease will better deﬁ  ne disease state and aid develop-
ment of nonintuitive treatments based on complex 
organ-system interaction patterns and their resolution 
in response to therapy. Th   ese should provide powerful 
insights into the basic biology of disease and how our 
treatments impact on multiple systems.
• Th   ere will be a better understanding of the metabolic 
nature of acute illness as well as metabolic adaptation 
from subcellular to organ-system levels.
• Th  ere will be better identiﬁ  cation of patient popula-
tions based on genetic factors and biomarkers. 
Revising our deﬁ   nitions of the phenotypes, such as 
sepsis and ARDS, with biological and genetic markers 
may facilitate therapy that is more eﬀ  ective, similar to 
the way in which some cancers are better managed by 
appreciation of the clinical phenotype in concert with 
biological and pathological markers.
•  Greater awareness of the time course of the evolving 
pathophysiology of the underlying disease process and 
improved diagnostics and genetic proﬁ  les of vulnera-
bility will lead to better selection of treatment type and 
intensity, improved timing of administration and 
discontinuation, and more sharply targeted therapies. 
Th  erapeutic targets will be better deﬁ  ned, based on 
abnormal, rather than normal, physiology and 
increased knowledge regarding the limits of adaptation 
to life-threatening illness. Monitoring relevant physio-
logical variables at the cellular level to detect tolerance 
or functional distress of the tissues as well as 
monitoring the response to treatment will facilitate 
selection of suitable therapies.
• Th  ere will be better models to test the eﬀ  ect  of 
complex interventions, often starting from prior to 
ICU admission and ﬁ  nishing after ICU discharge.
• Better use of functional hemodynamic monitoring 
principals will guide resuscitation on macrocirculatory 
and microcirculatory levels.
• Th  ere will be less focus on individual aspects of care 
and a greater emphasis on how diﬀ  erent components 
of the ‘package’ of ICU treatments work together to 
improve outcomes.
• Th   ere will be better identiﬁ  cation of the impact of how 
health care systems are managed and how care is 
provided to patient populations and to individuals on 
the prevalence rates and outcomes of many critical 
illnesses.
•  Improved utilization of electronic tools and 
technologies will streamline the processes of care 
delivery. Interactive patient-speciﬁ  c guidelines available 
at the bedside will assist in decision-making for hemo-
dynamic and respiratory management. Regulatory 
agencies in various countries will expect clinician 
compliance with performance metrics based on these 
guidelines for management of critical illness. Th  ere 
will also be increasing emphasis on reducing demands 
for blood ﬂ   ow, ventilation, and oxygenation rather 
than applying potentially noxious therapies to boost 
their supply.
• Safe and eﬀ   ective mechanical assist devices (for 
example, left ventricular assist devices and impellers) 
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will continue to be developed. Incorporation of 
improved extracorporeal and intravenacaval respira-
tory gas exchangers into bedside practice will further 
reduce VILI and minimize or obviate the need for 
intubation.
•  Leveraging of communication technology will extend 
scarce critical care expertise to underserved settings 
and improve care uniformity throughout the 24-hour 
cycle. Th   is may incorporate the use of remote 
medicine/telemedicine.
• Further focus on perfecting sedation and analgesia 
stratagems will maintain comfort and near alertness 
while allowing quality sleep and avoidance of delirium. 
Th  ere will be earlier mobilization to reduce muscle 
wasting and contractures and to facilitate recovery, 
and there will be greater input into the management of 
the long-term sequelae of critical illness.
• A smoother continuum between prehospital care, 
emergency care, and pre-ICU and post-ICU care, with 
more interventions beyond the ICU walls, will prevent 
or accelerate ICU admission and limit complications 
and ‘rebound’ following ICU discharge.
• Th  ere will be continuing and expanding international 
collaborations, with the creation of large databases of 
patients and conduct of multicenter observational and 
interven tional  studies.
• Increased  eﬀ  orts will be made to make the ICU more 
attractive to young physicians and researchers to 
ensure continued recruitment of enthusiastic and 
skilled intensivists. Simulation will play an increased 
role in education and in the development of new skills.
•  Basic ICU facilities, training programs, and internet-
based decision support tools will be established to 
improve critical care in developing countries.
We must, however, recognize that these advances in 
technology and understanding will be challenged by 
increasing strictures in health-care funding. Intensive 
care is expensive care. It is thus incumbent upon us not 
to allow care to be rationed by external forces but to 
recognize the limitations of what we can oﬀ  er and when 
ongoing care is futile. In these cases, we should not 
needlessly waste resources on prolonging death but 
should shift the emphasis toward easing the dying 
process and supporting the patient’s family and friends.
Conclusions
It is diﬃ   cult to document and quantify the improvements 
that have been made in the last 30 years. For many 
problems, mortality rates have not changed much overall; 
in certain disease processes (for example, sepsis and 
ARDS), they may have decreased somewhat. However, 
the population that we are treating in our ICUs has 
changed and is getting older and sicker. For example, the 
mean age of ICU patients was over 60 years in recent 
studies [23,24], so it is diﬃ     cult to compare current 
statistics with those of 30 years ago. Given the growing 
fragility of our patients, even maintaining historical 
morbidity and mortality rates could signal improvements 
in care. Th   e aging of populations in many countries will 
place increasing demands on ICU resources that are 
already limited and expensive in many areas of the world.
Th  ere are clearly areas of intensive care medicine in 
which we have made little progress and others in which 
much progress has been achieved. As we look forward to 
the next three decades of intensive care, it is important to 
learn from past failures and to build on our successes to 
create a more eﬀ  ective,  eﬃ   cient,  and  evidence-based 
discipline for the future.
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